News

Published on 6 Oct 2022 on Benzinga via Yahoo Finance

Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction


Article preview image

Cyclerion Therapeutics Inc (NASDAQ: CYCN) is reprioritizing development programs and focusing resources and capabilities on candidates for mitochondrial diseases.The company has been exploring the pharmacology of sGC stimulation with once-daily CY6463 in signal-seeking studies in three patient populations.From now on, Cyclerion will focus future development of CY6463 concentrating first on the development of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS)."We look forward to discussions with regulators later this year and sharing more detailed development plans early in the new year," said Peter Hecht, Cyclerion CEO.Also Read: Why Cyclerion Therapeutics Stock Is Getting HammeredThe company is preparing to meet with the FDA to discuss the CY6463 development program.Cyclerion is also developing CY6463 in Cognitive Impairment Associated with Schizophrenia (CIAS) and Alzheimer's Disease with Vascular Pathology (ADv) patients.Cyclerion says CY3018 is well-suited for treating CIAS and other neuropsychiatric indications. Cyclerion is completing pre-IND activities for CY3018 and is looking to secure a partnership or other funding mechanism to develop the program in the future.The company capped enrollment in its ongoing ADv clinical study. Data from the ADv study are expected in the first half of 2023.The company reduced its workforce by approximately 45% to 16 full-time employees and will take a one-time charge of $1.9 million and realize annual savings of around $4.1 million.Price Action: CYCN shares are down 42.58% at $0.5399 on the last check Thursday.

See more from Benzinga

NASDAQ.CYCN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
12 Best Biotech Penny Stocks to Invest In

In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip ou...

Insider Monkey via Yahoo Finance 24 Mar 2024

Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses

Insiders who bought US$1.95m worth of Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) stock at an av...

Simply Wall St. via Yahoo Finance 29 Nov 2023

The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion...

Peter Hecht, the co-founder and CEO of embattled biotech Cyclerion Therapeutics Inc. (Nasdaq: CYC...

American City Business Journals 5 Aug 2023

Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company...

Cyclerion Therapeutics Inc (NASDAQ: CYCN) has agreed to sell two of its assets - zagociguat (form...

Benzinga via Yahoo Finance 12 May 2023

GreenLight Biosciences lays off a quarter of its team

GreenLight Biosciences Holdings Inc. is laying off a quarter of its staff eight months after it w...

American City Business Journals 27 Oct 2022

Cyclerion Therapeutics lays off nearly half of workforce

Cyclerion Therapeutics Inc. is culling its workforce as it narrows its focus to mitochondrial...

American City Business Journals 7 Oct 2022

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.15% By Investing.com

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.15%

Investing.com 6 Oct 2022

Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction

Cyclerion Therapeutics Inc (NASDAQ: CYCN) is reprioritizing development programs and focusing res...

Benzinga via Yahoo Finance 6 Oct 2022

U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.15%

U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.15%

Investing.com 6 Oct 2022

Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates

Cyclerion Therapeutics, Inc. (CYCN) came out with a quarterly loss of $0.31 per share versus the ...

Zacks via Yahoo Finance 10 Aug 2022